In the BioHarmony Drug Report Database
Imatinib
Gleevec, Glivec (imatinib) is a small molecule pharmaceutical. Imatinib was first approved as Gleevec on 2001-05-10. It is used to treat dermatofibrosarcoma, hypereosinophilic syndrome, lymphoid leukemia, myelodysplastic-myeloproliferative diseases, and myeloid leukemia amongst others in the USA. It has been approved in Europe to treat bcr-abl positive chronic myelogenous leukemia, dermatofibrosarcoma, gastrointestinal stromal tumors, hypereosinophilic syndrome, and myelodysplastic-myeloproliferative diseases amongst others. It is known to target tyrosine-protein kinase ABL1. Gleevec’s patent is valid until 2021-12-19 (FDA).
Trade Name
|
Glivec |
|---|---|
Common Name
|
imatinib |
ChEMBL ID
|
CHEMBL941 |
Indication
|
bcr-abl positive chronic myelogenous leukemia, dermatofibrosarcoma, gastrointestinal stromal tumors, hypereosinophilic syndrome, lymphoid leukemia, myelodysplastic-myeloproliferative diseases, myeloid leukemia, precursor cell lymphoblastic leukemia-lymphoma, systemic mastocytosis |
Drug Class
|
Tyrosine kinase inhibitors |
Image (chem structure or protein)